
    
      This study has two stages with the Stage I expected from Day 1 through Month 30, and the
      Stage II expected post-Month 30 to Month 90. The Stage I study is a case-driven study which
      aims to accrue at least 20 cases of HPV 31/33/45/52/58-related 12-month persistent infection
      and at least 39 cases of HPV 31/33/45/52/58-related 6-month persistent infection by
      completion of Month 30 visit. The Stage II study is a case-driven study which aims to accrue
      at least 12 cases of HPV 31/33/45/52/58-related cervical intraepithelial neoplasia grade 2 or
      3 (CIN 2/3), cervical adenocarcinoma in situ (AIS), and cervical cancer observed in both
      Stage I and Stage II, by completion of Month 90 visit.
    
  